CJC-1295 is a synthetic GHRH analog that stimulates GH release, commonly stacked with ipamorelin, and is used by the community for sleep quality and recovery, muscle growth and fat loss, and anti-aging. Typical protocols involve doses of 200 mcg/day, although reported doses range from 100 mcg to 25 mg/day. Sleep and dream effects are commonly reported, while injection-site reactions and other side effects have not been a consistent theme in community reports.
Data last updated
Measured on 5 of 6 axes
Evidence shape
The evidence for CJC-1295 is limited to exploratory human studies, with two treatment studies and two diagnostic or mechanistic studies reported. All four indications mapped are thin or exploratory, and there are no completed trials due to a 100% withdrawal rate in the sole registered study. While preclinical research exists, no human data support clinical use for indications such as HIV-associated lipodystrophy or visceral fat reduction.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
HIV-associated lipodystrophy — visceral fat reduction
1 study
Treatment studies
2 studies
Diagnostic & mechanistic studies
2 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Grouped from 2 published human studies — weighted by study count, not incidence (the papers report no rates).
Anecdotal side effects
price offers can be sorted by column · 20 out-of-stock offers not shown
How CJC-1295 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In research trials, CJC-1295 was given at 30–60 µg per kilogram of body weight each week; no fixed milligram dose was specified.
Clinician practice typically uses 1–2 mg of CJC‑1295 subcutaneously, either once daily or twice daily, with no established cycling schedule.
Community users typically take 100 mcg subQ; most do not specify a schedule, while a small minority follow a 5‑days‑on/2‑days‑off cycle.